Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction.

Gibson, C Michael; Kastelein, John JP; Phillips, Adam T; Aylward, Philip E; Yee, Megan K; Tendera, Michal; Nicholls, Stephen J; Pocock, Stuart; Goodman, Shaun G; Alexander, John H; +11 more... Lincoff, A Michael; Bode, Christoph; Duffy, Danielle; Heise, Mark; Berman, Gail; Mears, Sojaita Jenny; Tricoci, Pierluigi; Deckelbaum, Lawrence I; Steg, P Gabriel; Ridker, Paul; Mehran, Roxana; (2021) Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction. American heart journal, 231. pp. 121-127. ISSN 0002-8703 DOI: https://doi.org/10.1016/j.ahj.2020.10.052

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1016/j.ahj.2020.10.052

Abstract

Item Type Article
Faculty and Department Faculty of Epidemiology and Population Health > Dept of Medical Statistics
PubMed ID 33065120
Elements ID 153297

Share

Download

Filename: 1-s2.0-S0002870320303355-main.pdf

Licence: Creative Commons: Attribution-Noncommercial-No Derivative Works 3.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar